Basel, 11 April 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the release of cobas® infinity 3.0, its proven global lab software solution for diagnostic laboratories to help laboratory leaders maintain high operational performance, quality, integration and security within their labs across multiple locations.
“Our cobas® infinity lab software solution will help labs – large and small - transform their operations for higher efficiencies, quality control and improve information-sharing and delivery of care to patients,” said Christian Hebich, Head of Solution Integration and Services, Roche Diagnostics. “These new features from cobas® infinity lab software solutions will help healthcare leaders integrate more, faster and maintain high quality while manageing the changing needs of clinicians and patients.”
One new feature further improves the intelligent routing of samples in high volume testing labs by dynamically adapting to changing lab conditions, such as priority testing, to reduce time to results. New improved quality control features ensure that the highest quality results are reported consistently, while new monitoring features secure high performance and stability of analysers and reagents 24/7 without additional costs. Finally, the addition of more work areas for different clinical laboratory disciplines (such as molecular, haematology, coagulation, etc.) enable lab staff to focus on what matters most to them. Additional features include an easy-to-use interface that allows lab technicians to customize and personalize their lab environment set-up across multiple sites.
The cobas® infinity lab software management solution helps laboratories integrate a wide range of key processes along the patient journey from ordering diagnostic tests to actual test results. It does this while automating the entire sample flow and bringing meaningful insights for informed decision making about patient care and treatment options. The well-established software solution is already installed in large and small laboratories in over 60 countries across the globe. Roche Diagnostics is a world market leader in providing integrated lab solutions to healthcare organisations.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.